The FDA is expected to announce its decision on a pending new drug application for Bunavail, a combination of buprenorphine and naloxone, for opioid dependence.

From the cardiovascular world, there will be more data examining the so-called "obesity paradox" in stroke and on the efficacy of ICDs in patients with less severe heart failure than typically seen in clinical trials of the devices.

Expect a bigger than usual to-do about marijuana's health effects later this week.